eventscribe

The eventScribe Educational Program Planner system gives you access to information on sessions, special events, and the conference venue. Take a look at hotel maps to familiarize yourself with the venue, read biographies of our plenary speakers, and download handouts and resources for your sessions.

close this panel
‹‹ Go Back

Florica Constantine

Johns Hopkins University



‹‹ Go Back

Yanxun Xu

Johns Hopkins University



‹‹ Go Back

Yili L. Pritchett

MedImmune



‹‹ Go Back

Please enter your access key

The asset you are trying to access is locked for premium users. Please enter your access key to unlock.


Email This Presentation:

From:

To:

Subject:

Body:

←Back IconGems-Print

231 – Biopharmaceutical Section Student Papers

ASID: A Bayesian Adaptive Subgroup-Identification Enrichment Design

Sponsor: Biopharmaceutical Section
Keywords: Hierarchical Bayesian Model, Clinical trial, Biomarker, Targeted therapies, Alzheimer's disease

Florica Constantine

Johns Hopkins University

Yanxun Xu

Johns Hopkins University

Yili L. Pritchett

MedImmune

Targeted therapies based on patients' baseline characteristics such as biomarkers have been growing interests for many diseases. Depending on the expression of specific biomarkers or their combinations, different patient subgroups could respond differently to the same treatment. An ideal design, especially at the proof of concept stage, should search for such subgroups and make dynamic adaptation as the trial goes on. When no prior knowledge is available on whether the treatment works on the all-comer population or only works on the subgroup defined by one biomarker or several biomarkers, it is necessary to estimate the subgroup effects adaptively based on the response outcomes and biomarker profiles from all the treated subjects at the interim analysis. To address this problem, we propose an adaptive subgroup-identification enrichment design, ASID, which can simultaneously search for predictive biomarkers, estimate the subgroups with differential treatment effects, and modify the study entry criteria at the interim analysis. We compare the ASID with an alternative adaptive enrichment design based on linear regression in a motivating Alzheimer's disease clinical trial, and demonstrate via simulation the superior performance of the ASID.

"eventScribe", the eventScribe logo, "CadmiumCD", and the CadmiumCD logo are trademarks of CadmiumCD LLC, and may not be copied, imitated or used, in whole or in part, without prior written permission from CadmiumCD. The appearance of these proceedings, customized graphics that are unique to these proceedings, and customized scripts are the service mark, trademark and/or trade dress of CadmiumCD and may not be copied, imitated or used, in whole or in part, without prior written notification. All other trademarks, slogans, company names or logos are the property of their respective owners. Reference to any products, services, processes or other information, by trade name, trademark, manufacturer, owner, or otherwise does not constitute or imply endorsement, sponsorship, or recommendation thereof by CadmiumCD.

As a user you may provide CadmiumCD with feedback. Any ideas or suggestions you provide through any feedback mechanisms on these proceedings may be used by CadmiumCD, at our sole discretion, including future modifications to the eventScribe product. You hereby grant to CadmiumCD and our assigns a perpetual, worldwide, fully transferable, sublicensable, irrevocable, royalty free license to use, reproduce, modify, create derivative works from, distribute, and display the feedback in any manner and for any purpose.

© 2017 CadmiumCD